{"id":"ac5afad9-cfd5-4b66-aa18-4d3aacf16560","name":"Synchron","slug":"synchron","description":"Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery. Founded by neurologist Tom Oxley, the company has raised over $345M in total funding including a $200M Series D in 2024. Synchron's COMMAND and SWITCH clinical trials demonstrated no serious device-related adverse events across 6 patients, and the FDA has approved the Stentrode for early feasibility studies. The company is based in New York with origins in Melbourne, Australia.","status":null,"founded":2016,"hq":"New York, NY, USA","fundingTotal":"200000000","type":"hardware","reviewStatus":"reviewed","sources":[{"url":"https://www.facebook.com/synchroninc/videos/-big-news-fda-approval-granted-for-synchrons-intent-trial-the-intent-trial-will-/2984514821739037/","title":"FDA approval granted for Synchron INTENT trial","sourceName":"Synchron"}],"keyFacts":[{"label":"CEO","value":"Tom Oxley (Founder, neurologist, Mount Sinai)"},{"label":"Total funding","value":"over $345M ($200M Series D 2024, $75M Series C 2022)"},{"label":"Product","value":"Stentrode (endovascular BCI implant, no open-brain surgery)"},{"label":"Clinical trials","value":"COMMAND (US, FDA-approved), SWITCH (Australia, 4 patients)"},{"label":"Safety","value":"No serious device-related adverse events in 6 patients"},{"label":"Target","value":"Patients with severe paralysis (ALS) to communicate via thought"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"createdAt":"2026-07-06T06:54:46.200Z","updatedAt":"2026-07-06T06:58:08.145Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/synchron","url":"https://registry.deploy.report/companies/synchron","name":"Synchron","description":"Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery. Founded by neurologist Tom Oxley, the company has raised over $345M in total funding including a $200M Series D in 2024. Synchron's COMMAND and SWITCH clinical trials demonstrated no serious device-related adverse events across 6 patients, and the FDA has approved the Stentrode for early feasibility studies. The company is based in New York with origins in Melbourne, Australia.","identifier":"ac5afad9-cfd5-4b66-aa18-4d3aacf16560","foundingDate":"2016","address":"New York, NY, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}